Historique
Chapitre
Methadone-associated mortality
(Mortalité liée à la méthadone)
Auteur(s) :
TRACHTENBERG, A. ;
54th semiannual meeting of the CEWG (June 24-27, 2003; St Louis, Missouri)
Année :
2004
Page(s) :
289-292
Langue(s) :
Anglais
Éditeur(s) :
Bethesda, MD : NIDA
Domaine :
Drogues illicites / Illicit drugs
Note générale :
In : Epidemiologic trends in drug abuse, Vol. II: Proceedings of the Community Epidemiology Work Group, 54th Meeting, St. Louis, Missouri, June 24-27, 2003, Bethesda, NIDA, 2004, 289-292
Résumé :
Dr. Trachtenberg began his presentation by providing some background information about his office - the Division of Pharmacologic Therapies (DPT), Center for Substance Abuse Treatment (CSAT), Substance Abuse and Mental Health Services Administration (SAMHSA). DPT is responsible for the regulation of the opioid treatment system, a responsibility assumed from the Federal Food and Drug Administration (FDA) in 2001. Currently, there are more than 200,000 patients being treated in opioid treatment programs (OTPs), formerly called methadone maintenance programs. In addition to methadone, levo-alpha-acetylmethadyl (LAAM) and buprenorphine are being dispensed and administered in opioid treatment programs. The DPT is also responsible for administering the Drug Addiction Treatment Act of 2000, which allows physicians to prescribe approved Schedule III, IV, and V narcotics (which at this time include only buprenorphine products) for the treatment of opioid addiction. Efforts are underway to provide medical examiners with the capability to test for buprenorphine. The National Institute on Drug Abuse (NIDA) has funded two Small Business Innovative Research (SBIR) grants to develop immunologic tests for buprenorphine. The goal is to have this testing capability in the field within the next 2 years. (Extract of the publication)
Affiliation :
Division of Pharmacologic Therapies, Center for Substance Abuse Treatment, Substance Abuse and Mental Health Services Administration, Rockville, MD, USA